DUBLIN--(BUSINESS WIRE)--The "Pseudomonas aeruginosa Pneumonia - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
Pseudomonas aeruginosa Pneumonia - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Pseudomonas aeruginosa Pneumonia (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Pseudomonas aeruginosa Pneumonia (Infectious Disease) pipeline guide also reviews key players involved in therapeutic development for Pseudomonas aeruginosa Pneumonia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities /Institutes, the molecules developed by Companies in Phase II and Preclinical stages are 1 and 5 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Pseudomonas aeruginosa Pneumonia (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Pseudomonas aeruginosa Pneumonia (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Pseudomonas aeruginosa Pneumonia (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Topics Covered:
Introduction
- Report Coverage
Pseudomonas aeruginosa Pneumonia - Overview
Pseudomonas aeruginosa Pneumonia - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
Pseudomonas aeruginosa Pneumonia - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
Pseudomonas aeruginosa Pneumonia - Companies Involved in Therapeutics Development
- Aridis Pharmaceuticals Inc
- AstraZeneca Plc
- Ayuvis Research Inc
- Pedanius Therapeutics Ltd
Pseudomonas aeruginosa Pneumonia - Drug Profiles
AVR-86 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
Gene Therapy for Pseudomonas aeruginosa Pneumonia - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
panobacumab - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
PED-014 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
PED-015 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
PED-019 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
Recombinant Enzyme for Pseudomonas Aeruginosa Pneumonia - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
Pseudomonas aeruginosa Pneumonia - Dormant Projects
Pseudomonas aeruginosa Pneumonia - Discontinued Products
Pseudomonas aeruginosa Pneumonia - Product Development Milestones
- Featured News & Press Releases
- Sep 26, 2017: Study Investigates Novel Immunotherapeutic Delivery Strategy for Preventing Infection with Antibiotic Resistant Bacteria
Appendix
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/3xl5wo
